BMS Pharmaceutical Korea announced on the 30th that Revlimid (Renalidomide) will be subject to benefits when administered in combination with Bortezomib/Dexamethasone, which is used to treat multiple myeloma patients, from the 1st of next month.

The law has proven its superior effectiveness and tolerance compared to current standard treatment through several clinical studies. Random allocation, public labeling, and phase 3 clinical trials (SWOG0777) in newly diagnosed patients with multiple myeloma confirmed significant progression-free survival and overall survival improvement compared to conventional RD (Revlimid+dexamethasone) therapy.

The median progression-free survival period of the